Rhumbline Advisers decreased its position in Enhabit, Inc. (NYSE:EHAB – Free Report) by 1.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 161,468 shares of the company’s stock after selling 2,307 shares during the period. Rhumbline Advisers’ holdings in Enhabit were worth $1,440,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in Enhabit by 25.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 966,515 shares of the company’s stock valued at $10,003,000 after purchasing an additional 193,675 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Enhabit in the fourth quarter valued at about $256,000. UBS Group AG raised its holdings in shares of Enhabit by 2.0% in the fourth quarter. UBS Group AG now owns 1,666,362 shares of the company’s stock valued at $17,247,000 after acquiring an additional 32,611 shares in the last quarter. Alberta Investment Management Corp lifted its stake in Enhabit by 56.8% in the fourth quarter. Alberta Investment Management Corp now owns 489,532 shares of the company’s stock worth $5,067,000 after acquiring an additional 177,360 shares during the period. Finally, 8 Knots Management LLC bought a new position in Enhabit during the 4th quarter worth about $1,968,000.
Analyst Upgrades and Downgrades
Separately, Bank of America reduced their price target on shares of Enhabit from $9.00 to $8.00 and set an “underperform” rating for the company in a report on Thursday, June 27th. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $9.35.
Enhabit Price Performance
EHAB opened at $8.05 on Friday. The firm has a market capitalization of $403.76 million, a PE ratio of -4.85 and a beta of 1.82. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.48 and a quick ratio of 1.48. The business’s 50-day moving average is $8.75 and its two-hundred day moving average is $9.37. Enhabit, Inc. has a 1 year low of $7.12 and a 1 year high of $12.19.
Enhabit (NYSE:EHAB – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. Enhabit had a negative net margin of 0.84% and a positive return on equity of 1.61%. The firm had revenue of $260.60 million during the quarter, compared to analyst estimates of $265.99 million. During the same quarter in the previous year, the business posted $0.04 EPS. Research analysts anticipate that Enhabit, Inc. will post 0.26 earnings per share for the current fiscal year.
Insider Transactions at Enhabit
In other Enhabit news, Director Jeffrey Bolton acquired 5,000 shares of the stock in a transaction dated Thursday, August 22nd. The stock was purchased at an average price of $8.01 per share, with a total value of $40,050.00. Following the transaction, the director now directly owns 78,877 shares of the company’s stock, valued at $631,804.77. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.90% of the company’s stock.
Enhabit Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Read More
- Five stocks we like better than Enhabit
- What is MarketRank™? How to Use it
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- MarketBeat Week in Review – 9/16 – 9/20
- Transportation Stocks Investing
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding EHAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enhabit, Inc. (NYSE:EHAB – Free Report).
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.